Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184738 | 0.95 | LMNA (0.44) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL12037545 | 0.94 | LMNA (0.43) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL13184737 | 0.92 | CYP3A4 (0.47) | LMNAHTTSMN1; SMN2CYP3A4 | |
| SCHEMBL764821 | 0.92 | LMNA (0.44) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL13184736 | 0.92 | CLPP (0.47) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL744851 | 0.91 | LMNA (0.46) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL747373 | 0.91 | LMNA (0.42) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL12037547 | 0.91 | CLPP (0.48) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL749011 | 0.90 | LMNA (0.44) | LMNAHTTSMN1; SMN2CYP3A4HRH3 | |
| SCHEMBL13500581 | 0.90 | CLPP (0.46) | LMNAHTTSMN1; SMN2CYP3A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-01 | — | — | US | disclosed |
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | LMNA 2967/4885HTT 622/4885SMN1; SMN2 4611/4885 |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | LMNA 2967/4885HTT 622/4885SMN1; SMN2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.